Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 25 of 34.
Aug 2013
8 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
29 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2013.
Jun 2013
3 Jun · Meeting
Company has fixed Book Closure from August 1, 2013 to August 7, 2013 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on August 07, 2013 and for payment of dividend for the year 2012-13.
May 2013
31 May · Dividend
Board of Directors of the Company at their meeting held on May 30, 2013 has interalia considered and approved the following : The final dividend at 50% (Rs.0.50 per equity share of Rs.1/-each) on the equity share capital of the Company for the year 2012-13 has been recommended, subject to approval of members. The Company in the month of February 2013 has paid an interim dividend of 100% (Rs.1.00 per equity share of Rs.1/-each) on the equity share capital of the Company for the year 2012-13.17 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013.Further, the Board will also consider recommendation of Final Dividend, if any, for the year 2012-13.
Apr 2013
Mar 2013
28 Mar · Updates
USFDA as per their website update has lifted the import alert for non-sterile products manufactured in its UNIT-VI cephalosporin facility based in Hyderabad, India, thereby, paving the way for resumption of exports of 9 products to the US market. The import alert was earlier imposed in February 2011. Prior to import alert, the Unit was having annual US sales of USD 33 million for the said products.
Feb 2013
14 Feb · Updates
Company's Unit VI, Cephalosporin oral formulations facility based in Hyderabad, India was re-inspected by US Food & Drug Administration (USFDA) in September 2012 and the Company has now received the Establishment Inspection Report (EIR) for the same. This facility was re-inspected by USFDA subsequent to an import alert imposed in February 2011.8 Feb · Dividend
Interim Dividend will be paid on or after February 27, 2013.8 Feb · Corporate action
Company has fixed Record Date as February 20, 2013 for the purpose of payment of interim Dividend 2012-13.8 Feb · Dividend
Board of Directors of the Company at its meeting held on February 07, 2013, has approved payment of an interim dividend @100% i.e. Re.1/- (Rupees One Only) per equity share of Re. 1 (Rupees One only) each to the members of the Company for Financial Year 2012-13.
Jan 2013
28 Jan · Disclosure
Compensation Committee of the Board on January 28, 2013, has considered and approved grant of 9,15,500 options at an exercise price of Rs. 187.40 per option (each option confer a right to one equity share of Re. 1/- each) under the Employees Stock Option Plan, 2006.21 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012.